Stocktoria
Oric Pharmaceuticals, Inc. ORIC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-04-24
Oric Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$143.0M | -$142.9M | -$110.8M | -$91.8M | -$78.9M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$129.5M | -$127.8M | -$100.7M | -$89.1M | -$78.7M |
| EPS (diluted) | $-1.47 | $-1.83 | $-1.96 | $-2.25 | $-2.07 |
| Operating cash flow | -$111.0M | -$112.7M | -$85.7M | -$75.1M | -$59.5M |
| Free cash flow | -$111.7M | -$113.8M | -$86.5M | -$77.2M | -$60.5M |
| Cash & equivalents | $45.7M | $59.4M | $23.4M | $66.8M | $226.0M |
| Total assets | $408.9M | $274.1M | $252.0M | $247.2M | $298.6M |
| Total liabilities | $24.5M | $31.0M | $27.9M | $24.8M | $25.7M |
| Shareholders' equity | $384.4M | $243.1M | $224.1M | $222.4M | $273.0M |
Source: SEC EDGAR filings · CIK 0001796280 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.